Skip to main content
OpenTrials
Completed

NCT Number: NCT04661748

Automated Alerts of Patient Deterioration vs. Routine Monitoring of High-risk Patients Admitted to Medical Wards

The primary aim of the current study is to assess the effect of continuous wireless vital signs monitoring with generation of real-time alerts compared to blinded monitoring without alerts on the cumulative duration of any severely deviating vital signs in patients admitted to general hospital wards with acute medical conditions. Patients admitted with medical conditions represents a large and heterogenous group occupying a substantial part of the total in-patient capacity in the Danish hospitals today. The hypothesize is that continuous vital signs monitoring, and real-time alerts will reduce the cumulative duration of severely deviating vital signs.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Bispebjerg and Frederiksberg Hospital

København NV, Region H, 2400, Denmark

About this study

Deterioration of patients on general hospital wards often goes unnoticed for prolonged periods of time. This delay can potentially result in severe adverse outcomes such as cardiopulmonary arrest and need for admission to the intensive care unit (ICU). These complications occur despite the fact that, in most cases, measurable changes in physiological vital signs, could identify patients at risk. Moreover, occurrence of complications increase treatment costs considerably underpinning the rationale of early detection of patient deterioration in both human and economic terms.

Monitoring of vital signs outside of ICU or telemetry units usually relies on intermittent manual assessments performed by clinical staff at intervals of up to 12 hours with the "Early Warning Score (EWS)", "Tidlig Opsporing af Kritisk Sygdom (TOKS)" or similar systems. However, significant deterioration may occur in-between these intervals, which may explain the EWS/TOKS score's proven lack of impact on morbidity and mortality in Danish hospitals.

Recent medico-technical advances have allowed for clinical use of small wireless wear-and-forget devices that continuously monitor various indices of cardiopulmonary status, ambulatory activity, temperature etc. Studies suggest that integration of continuous monitoring into automated patient surveillance systems more often detects cardiorespiratory instability and may decrease number of Emergency Response Team activations, ICU transfers, length of hospital stay, morbidity and mortality but further randomized controlled trials (RCTs) are needed to confirm this. Other advantages may be a decrease in the time required for vital signs measurement and recording compared to routine monitoring and overall health care cost savings with return-on-investment estimates ranging from 127%-1739%.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Inclusion and randomization possible within 12 hours of fulfilling all other inclusion criteria below.
  • Adult patients (≥18 years).
  • At least one (additional) expected overnight stay.
  • High-risk medical admission, defines as EITHER:
  • one or more of the following symptoms or tentative diagnoses: Pneumonia, dyspnea, acute coronary syndrome, new onset heart failure or sepsis WITH two or more of the following deviations in vital signs recorded at one time point within 48 hours of admission:
  • Respiratory rate ≥ 21 min-1 or ≤ 7 min-1
  • Oxygen saturation of arterial hemoglobin ≤ 93 %
  • Pulse rate ≥ 111 min-1 or ≤ 40 min-1
  • Systolic blood pressure ≤ 100 mmHg or > 200 mmHg
  • Temperature > 39 °C or ≤ 35,9 °C
  • Any alteration in mental status
  • Any oxygen supplementation

OR

○ Discharged from ICU-stay lasting ≥ 24 hours regardless of cause of ICU-admission.

Exclusion criteria

  • Patient expected not to cooperate with study procedures.
  • Allergy to plaster or silicone.
  • Patients admitted for palliative care only (i.e. no active treatment).
  • Planned admission to unit using continuous vital sign monitoring (i.e. an intermediary care/telemetry unit).
  • Patients previously enrolled in the studies WARD-COPD (H-18026653) or WARD-Surgery (H-17033535).
  • Patients previously enrolled in the surgical ward RCT
  • A pacemaker or Implantable Cardioverter Defibrillator (ICD) device.
  • Inability to give informed consent.

Treatment and study plan

real time alarm of deviating vital signs

Device

Intervention consists of actively alerting staff personnel if physiologic vital signs, deviates from certain thresholds

Primary outcomes

  1. Cumulative duration of one or more of the following deviations in vital signs during the first five days of admission or until discharge:

    Time frame: 5 days after inclusion or until discharge

    ● SpO2 < 85%

  2. Cumulative duration of one or more of the following deviations in vital signs during the first five days of admission or until discharge:

    Time frame: 5 days after inclusion or until discharge

    • Respiratory rate ≤ 5 min-1
    • Respiratory rate > 24 min-1
  3. Cumulative duration of one or more of the following deviations in vital signs during the first five days of admission or until discharge:

    Time frame: 5 days after inclusion or until discharge

    • Heart rate > 130 min-1
    • Heart rate ≤ 30 min-1
  4. Cumulative duration of one or more of the following deviations in vital signs during the first five days of admission or until discharge:

    Time frame: 5 days after inclusion or until discharge

    • Systolic blood pressure ≤ 90 mmHg
    • Systolic blood pressure > 220 mmHg
  5. Cumulative duration of one or more of the following deviations in vital signs during the first five days of admission or until discharge:

    Time frame: 5 days after inclusion or until discharge

    ● Atrial fibrillation

  6. Cumulative duration of one or more of the following deviations in vital signs during the first five days of admission or until discharge:

    Time frame: 5 days after inclusion or until discharge

    ● Circulatory failure

    • Systolic blood pressure < 100 mmHg AND
    • Heart rate >110 min-1 (for more than 30 minutes) OR heart rate >130 min-1 (for more than 5 minutes) OR heart rate < 50 (for more than 30 minutes) AND/

Secondary outcomes

  1. Frequency and duration of deviations in vital signs

    Time frame: 5 days after inclusion or until discharge

    Frequency of each of the deviations in vital signs. List of vital signs, and normal limits detailed in protocol

Other outcomes

  1. Number of patients with any adverse clinical outcomes

    Time frame: 30 days after inclusion

    Any adverse events. Criteria for each defined in protocol. Adverse events will be manually categorised as a 'Severe adverse event' (SAE), or simple 'adverse event' (AE).

  2. Length of hospital stay (LOS)

    Time frame: 6 months after inclusion

    Lenght of hospital stay

  3. Total patient-related healthcare expenses in patients experiencing adverse clinical outcomes compared to patients without such outcomes and the effect of the study intervention on expenses

    Time frame: 2 years

    Total patient-related healthcare expenses in patients experiencing adverse clinical outcomes compared to patients without such outcomes and the effect of the study intervention on expenses

  4. Staff response time (interventions group only)

    Time frame: 5 days after inclusion

    Time from the staff is notified by app, until they respond by selecting 'check on patient' in app Stratified according to time of day

Sponsors and collaborators

Lead sponsor

University Hospital Bispebjerg and Frederiksberg

Other

Collaborators

  • Aalborg University Hospital
  • Hvidovre University Hospital
  • Odense University Hospital
  • Rigshospitalet, Denmark

Registry information

Official study title

Continuous Wireless Monitoring of Vital Signs and Automated Alerts of Patient Deterioration vs. Routine Monitoring of High-risk Patients Admitted to Medical Wards

Acronym: WARD

Important dates

Study start
2022
Primary completion
2023
Study completion
2024
First posted
Dec 10, 2020
Registry last updated
Apr 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.